According to the Brigham researchers' next-generation sequencing, changing existing cancer care standards might allow around 6,000 more patients in the United States to benefit from immunotherapy treatment each year.
A group of researchers led by Nanyang Technological University, Singapore (NTU Singapore) discovered that a cancer medicine that is currently on the market might be modified to target a subgroup of malignancies that are frequently linked with poor outcomes and lack focused therapy choices.